Functional and specific antibody responses in adult volunteers in new zealand who were given one of two different meningococcal serogroup B outer membrane vesicle vaccines
- PMID: 17494638
- PMCID: PMC1951067
- DOI: 10.1128/CVI.00039-07
Functional and specific antibody responses in adult volunteers in new zealand who were given one of two different meningococcal serogroup B outer membrane vesicle vaccines
Abstract
This study presents detailed analyses of total and specific serum antibody levels among 26 and 24 adult volunteers before vaccination and after the third dose of the meningococcal serogroup B outer membrane vesicle (OMV) vaccines MeNZB and MenBvac, respectively, in a clinical trial in New Zealand (V. Thornton, D. Lennon, K. Rasanathan, J. O'Hallahan, P. Oster, J. Stewart, S. Tilman, I. Aaberge, B. Feiring, H. Nokleby, E. Rosenqvist, K. White, S. Reid, K. Mulholland, M. J. Wakefield, and D. Martin, Vaccine 24:1395-1400, 2006). With the homologous vaccine strains as targets, both vaccines induced significant increases in serum bactericidal and opsonophagocytic activities and in the levels of immunoglobulin G (IgG) to OMV antigens in an enzyme-linked immunosorbent assay (ELISA) and to live meningococci by flow cytometry. They also induced high levels of activity against the heterologous strains, particularly in terms of opsonophagocytic activity and IgG binding to live bacteria. The antibody levels with the homologous and heterologous strains in the four assays showed high and significant positive correlations. Specific IgG binding to 10 major OMV antigens in each vaccine was measured by scanning of immunoblots; ELISAs for two antigens, lipopolysaccharide and Neisseria surface protein A (NspA), were also performed. Both vaccines elicited significant increases in IgG binding to all homologous and heterologous OMV antigens except NspA. The total IgG band intensity on the blots correlated significantly with the IgG levels determined by the OMV ELISA and flow cytometry. In conclusion, the results of the various immunological assays showed that both OMV vaccines gave rise to high levels of specific and cross-reacting antibodies.
Figures

Similar articles
-
Re: Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5 year olds in New Zealand, Oster P, O'Hallahan J, Aaberge I, Tilman S, Ypma E, Martin D. Vaccine 2007;25(16):3075-9.Vaccine. 2007 Sep 28;25(39-40):6835; author reply 6835-6. doi: 10.1016/j.vaccine.2007.06.025. Epub 2007 Jun 19. Vaccine. 2007. PMID: 17875437 No abstract available.
-
Re: Safety review: Two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease, Nokleby H, Aavitsland P, O'Hallahan J, Feiring B, Tilman S, Oster P. Vaccine 2007;25(16):3080-4.Vaccine. 2007 Sep 28;25(39-40):6833; author reply 6833-4. doi: 10.1016/j.vaccine.2007.06.024. Epub 2007 Jun 21. Vaccine. 2007. PMID: 17630051 No abstract available.
-
Immunogenicity and safety of a combination of two serogroup B meningococcal outer membrane vesicle vaccines.Clin Vaccine Immunol. 2007 Sep;14(9):1062-9. doi: 10.1128/CVI.00094-07. Epub 2007 Jul 18. Clin Vaccine Immunol. 2007. PMID: 17634513 Free PMC article. Clinical Trial.
-
Predicted vs observed effectiveness of outer membrane vesicle (OMV) vaccines against meningococcal serogroup B disease: Systematic review.J Infect. 2017 Aug;75(2):81-94. doi: 10.1016/j.jinf.2017.05.001. Epub 2017 May 6. J Infect. 2017. PMID: 28487177
-
Recent developments in vaccines to prevent meningococcal serogroup B infections.Curr Opin Mol Ther. 2003 Feb;5(1):33-8. Curr Opin Mol Ther. 2003. PMID: 12669468 Review.
Cited by
-
Type 5 secretion system antigens as vaccines against Gram-negative bacterial infections.NPJ Vaccines. 2024 Sep 1;9(1):159. doi: 10.1038/s41541-024-00953-6. NPJ Vaccines. 2024. PMID: 39218947 Free PMC article. Review.
-
Neisseria gonorrhoeae lipooligosaccharide glycan epitopes recognized by bactericidal IgG antibodies elicited by the meningococcal group B-directed vaccine, MenB-4C.Front Immunol. 2024 Feb 19;15:1350344. doi: 10.3389/fimmu.2024.1350344. eCollection 2024. Front Immunol. 2024. PMID: 38440731 Free PMC article.
-
An OMV Vaccine Derived from a Capsular Group B Meningococcus with Constitutive FetA Expression: Preclinical Evaluation of Immunogenicity and Toxicity.PLoS One. 2015 Sep 21;10(9):e0134353. doi: 10.1371/journal.pone.0134353. eCollection 2015. PLoS One. 2015. PMID: 26390123 Free PMC article.
-
Cellular and molecular biology of Neisseria meningitidis colonization and invasive disease.Clin Sci (Lond). 2010 Feb 9;118(9):547-64. doi: 10.1042/CS20090513. Clin Sci (Lond). 2010. PMID: 20132098 Free PMC article. Review.
-
OpcA and PorB are novel bactericidal antigens of the 4CMenB vaccine in mice and humans.NPJ Vaccines. 2023 Apr 12;8(1):54. doi: 10.1038/s41541-023-00651-9. NPJ Vaccines. 2023. PMID: 37045859 Free PMC article.
References
-
- Aase, A., G. Bjune, E. A. Hoiby, E. Rosenqvist, A. K. Pedersen, and T. E. Michaelsen. 1995. Comparison among opsonic activity, antimeningococcal immunoglobulin G response, and serum bactericidal activity against meningococci in sera from vaccinees after immunization with a serogroup B outer membrane vesicle vaccine. Infect. Immun. 633531-3536. - PMC - PubMed
-
- Aase, A. T. K. Herstad, L. M. Næss, T. E. Michaelsen, and D. R. Martin. 2004. Abstr. 14th Int. Pathogenic Neisseria Conf., p. 140.
-
- Aase, A., E. A. Hoiby, and T. E. Michaelsen. 1998. Opsonophagocytic and bactericidal activity mediated by purified IgG subclass antibodies after vaccination with the Norwegian group B meningococcal vaccine. Scand. J. Immunol. 47388-396. - PubMed
-
- Aase, A., L. M. Naess, R. H. Sandin, T. K. Herstad, F. Oftung, J. Holst, I. L. Haugen, E. A. Hoiby, and T. E. Michaelsen. 2003. Comparison of functional immune responses in humans after intranasal and intramuscular immunisations with outer membrane vesicle vaccines against group B meningococcal disease. Vaccine 212042-2051. - PubMed
-
- Ala'aldeen, D. A., H. A. Davies, and S. P. Borriello. 1994. Vaccine potential of meningococcal FrpB: studies on surface exposure and functional attributes of common epitopes. Vaccine 12535-541. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical